The GHIT Fund is pleased to announce that Dr. Nicholas Cammack, Interim Chief Research Programmes Officer at Wellcome, has been appointed as a new member of GHIT’s Board of Directors.

At Wellcome, Dr. Cammack oversees a diverse portfolio of discovery research and addresses critical health challenges, including mental health, infectious diseases, and the impact of climate on health. He has led significant initiatives such as the £80 million Snakebite program and Wellcome's COVID-19 therapeutics efforts, including his involvement with the UK Government’s Antiviral Task Force. Prior to Wellcome, Dr. Cammack was Head of the GSK Tres Cantos Medicines Development Campus in Madrid, where he led the discovery of treatments for neglected diseases like malaria, tuberculosis, Chagas disease, and Leishmaniasis, collaborating with organizations such as Medicines for Malaria Venture, TB Alliance, and the Bill & Melinda Gates Foundation.

For more information on the Board of Directors, please visit:

https://www.ghitfund.org/leadership/boardofdirectors/en